MedTrace Logo

Pilot Study of Pancreatic Cancer Screening

NCT05058846 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-05-02

No results posted yet for this study

Summary

This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.

Conditions

  • Pancreatic Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood, tissue, and saliva collection

PROCEDURE

Magnetic Resonance Cholangiopancreatography

Undergo MRCP

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Endoscopic ultrasound

Undergo endoscopic ultrasound

OTHER

Questionnaires

Complete the following questionnaires: Pancreatic Cancer Knowledge Survey, Pancreatic Cancer Worry Scale, Disease Specific Perceived Risk Survey, eGene Questionnaire

Sponsors & Collaborators

Principal Investigators

  • Pamela N Munster, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2032-01-31
Completion
2032-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05058846 on ClinicalTrials.gov